Acadia Healthcare Beats Q2 Revenue, Lifts 2026 Cash Flow Outlook by 23%
ACHC has more than doubled off its 52-week low of $11.43.
Summary
Acadia Healthcare posted Q2 revenue of $865.84M, beating the $844.23M consensus, and raised its full-year operating cash flow guidance to $350-$400M from $285-$325M — a 23% increase at the midpoint. Adjusted EBITDA of $149.20M edged past estimates despite a $39.3M jump in liability costs, including a $28.6M reserve adjustment. Acute inpatient volumes grew 5.5%, driven by 240 new beds, while revenue was held back by timing of supplemental payments in Florida and Tennessee. This follows a strong Q1 and a $105M jury award against a subsidiary in May, which may be contributing to the reserve build. The raised cash flow outlook signals confidence in underlying operations, though cost pressures bear watching.
Updates
· SEC 8-K — The 8-K includes the full earnings release and slide presentation, with adjusted EPS of $0.38, net income of $10.9M, and updated full-year guidance: revenue $3.40-$3.45B, adjusted EBITDA $590-$615M, adjusted EPS $1.45-$1.60, operating cash flow $350-$400M, capex $235-$255M.
At the time of this announcement, ACHC was trading at $30.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $11.43 to $35.83. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.